Nautilus Biotechnology Inc expected to post a loss of 14 cents a share - Earnings Preview

Nautilus Biotechnology

26/02/2024 15:12

* Nautilus Biotechnology Inc  NAUT.OQ   NAUT.O  is expected
to show no change in quarterly revenue when it reports 
results on February 28 for the period ending December 31 2023
    * 
    * ​LSEG's mean analyst estimate for Nautilus Biotechnology
Inc is
for a loss of 14 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Nautilus
Biotechnology Inc is $5.00​, above​ its last closing price
of $2.81. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.17       -0.17      -0.13     Beat    22.4
 Jun. 30 2023  -0.14       -0.15      -0.13     Beat    13.3
 Mar. 31 2023  -0.16       -0.17      -0.12     Beat    28​
 Dec. 31 2022  -0.14       -0.15      -0.11     Beat    28.3
 ​​Sep.        -0.15       -0.15      -0.11     Beat    25.4
 30 2022                                                
 Jun. 30 2022  -0.17       -0.17      -0.12     Beat    28.4​
 Mar. 31 2022  -0.16       -0.16      -0.13     Beat    17
 Dec. 31 2021  -0.14       -0.13      -0.13     Met     1.9
 This summary was machine generated February 26 at 15:12 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)